Alnylam Pharmaceuticalsvs.Moderna
ALNY vs MRNA · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Moderna is about 2.9× larger than Alnylam Pharmaceuticals by market cap; year to date, Moderna leads (+568.0% vs −43.5%).
Side by side
| ALNY | MRNA | |
|---|---|---|
| Market cap | $30B | $88.6B |
| Price | $232.68 | $225.00 |
| Today | +3.6% | +14.2% |
| Return YTD | −43.5% | +568.0% |
| Return 1Y | −50.2% | +605.6% |
| Since June 26, 2026 | −20.1% | +234.5% |
| P/E | 37.2 | — |
| P/S | 6.3 | 39.8 |
| P/B | 22.2 | 13.1 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Alnylam PharmaceuticalsALNY
Turns RNA interference into drugs, mostly for rare and cardiovascular disease.
Full ALNY profile →ModernaMRNA
Built on mRNA, the technology behind its covid vaccine. The pipeline pushes the same platform into further vaccines and into oncology.
Full MRNA profile →More ALNY & MRNA comparisons
Other head-to-heads in the Biotech & innovation segment.
See where ALNY and MRNA sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →